Bio-Gene TechnologyASX:BGT Quick Ratio is 4.31 as of Dec. 2025, which is 46% below its 10-year median of 7.92. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Bio-Gene Technology ranks better than 55.2% on this metric.
Bio-Gene Technology has a quick ratio of 4.31. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bio-Gene Technology's Quick Ratio or its related term are showing as below:
ASX:BGT'
s Quick Ratio Range Over the Past 10 Years
Min: 3.38 Med: 7.92 Max: 31.81
Current: 4.31
During the past 8 years, Bio-Gene Technology's highest Quick Ratio was 31.81. The lowest was 3.38. And the median was 7.92.
ASX:BGT's Quick Ratio is ranked better than 55.2% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:BGT: 4.31
Bio-Gene Technology (ASX:BGT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bio-Gene Technology Quick Ratio Related Terms
Bio-Gene Technology Quick Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Gene Technology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BGT vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Bio-Gene Technology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bio-Gene Technology's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gene Technology (ASX:BGT) has a Quick Ratio of 4.31 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bio-Gene Technology and its competitors. This is 46% below median its historical median of 7.92. Over the past decade, Bio-Gene Technology's Quick Ratio has ranged from 3.38 to 31.81. According to the industry distribution chart, Bio-Gene Technology ranks #633 out of 1413 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Bio-Gene Technology's Quick Ratio too high?
Bio-Gene Technology's current Quick Ratio of 4.31 is 46% below median its 10-year median of 7.92. Over the past 10 years, this metric has ranged from a low of 3.38 to a high of 31.81. The Biotechnology industry median Quick Ratio is 3.60. Bio-Gene Technology's value of 4.31 is 19.7% above this industry median. Based on the distribution chart, Bio-Gene Technology ranks #633 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint.
How does Bio-Gene Technology's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #633 out of 1413 companies for Quick Ratio. This puts Bio-Gene Technology in the upper half of its industry. The industry median Quick Ratio is 3.60. Bio-Gene Technology's value of 4.31 is 19.7% above this benchmark. Historically, Bio-Gene Technology's own Quick Ratio has ranged from 3.38 to 31.81 over the past decade. While the company's 10-year median is 7.92 vs. the industry median of 3.60, Bio-Gene Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Gene Technology's current Quick Ratio of 4.31 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bio-Gene Technology and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current Quick Ratio is 4.31, which is 46% below median its own 10-year median of 7.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Quick Ratio of 4.31. The current Quick Ratio is 4.31, which is 46% below median its 10-year median of 7.92 and 19.7% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Quick Ratio is 4.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 